A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

NCT02955212 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: Upadacitinib
DRUG: Placebo

Sponsor

AbbVie